Literature DB >> 2838255

Bone-resorbing agents affect the production and distribution of procollagenase as well as the activity of collagenase in bone tissue.

J M Delaisse1, Y Eeckhout, G Vaes.   

Abstract

The participation of collagenase in bone resorption has been investigated by assaying the procollagenase extracted from fetal mouse calvaria cultured under a variety of conditions, and by evaluating its ability to degrade bone collagen. Procollagenase was found in two separate pools, one requiring demineralization for its extraction, the other not. Culturing the bones with PTH, 1,25-dihydroxyvitamin D3, prostaglandin E2, interleukin-1, tumor necrosis factor-alpha, catabolin, retinoic acid, or endotoxin (but not with heparin) induced resorption, enhanced lysosomal enzyme release, and markedly increased the procollagenase content of the second pool. The PTH-induced increase in procollagenase was dose dependent and paralleled the extent of calcium loss and lysosomal enzyme release. The increase in procollagenase was found in bone, periosteum, and sutures, where its distribution was similar to that of nonmineralized collagen. The increase in procollagenase was abolished by cycloheximide, but not by indomethacin, hydroxyurea, glucocorticoids, acetazolamide, bisphosphonates, or calcitonin. Calcitonin and bisphosphonates almost completely inhibited the PTH-induced Ca loss and lysosomal enzyme release, but only partially inhibited the PTH-induced loss of collagen. The latter was, however, completely prevented by the collagenase inhibitor, CI-1. CI-1 also partially inhibited the PTH-induced Ca loss. Moreover, collagen degradation occurred in PTH-precultured calvaria (but not in noncultured controls) when incubated in a buffer under nonviable and nondemineralizing conditions. This degradation was inhibited by collagenase inhibitors, either CI-1 or the natural tissue inhibitor of metalloproteinases. This work thus indicates that the resorption of fetal bone explants proceeds along with an accumulation of procollagenase, primarily within their nonmineralized matrix. Moreover the results suggest that collagenase is likely to participate in the degradation of the nonmineralized collagen of the bone explants. Whether it also participates in the degradation of the collagen of the mineralized matrix remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838255     DOI: 10.1210/endo-123-1-264

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Distribution of matrix metalloproteinases and their inhibitor, TIMP-1, in developing human osteophytic bone.

Authors:  S Bord; A Horner; R M Hembry; J J Reynolds; J E Compston
Journal:  J Anat       Date:  1997-07       Impact factor: 2.610

2.  Identification and characterization of Runx2 phosphorylation sites involved in matrix metalloproteinase-13 promoter activation.

Authors:  Nagarajan Selvamurugan; Emi Shimizu; Minnkyong Lee; Tong Liu; Hong Li; Nicola C Partridge
Journal:  FEBS Lett       Date:  2009-03-03       Impact factor: 4.124

3.  Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model.

Authors:  S M Eck; P J Hoopes; B L Petrella; C I Coon; C E Brinckerhoff
Journal:  Breast Cancer Res Treat       Date:  2008-07-03       Impact factor: 4.872

4.  Possible role and mechanism of action of dissolved calcium in the degradation of bone collagen by lysosomal cathepsins and collagenase.

Authors:  Y Eeckhout
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

5.  Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase.

Authors:  P A Hill; A J Docherty; K M Bottomley; J P O'Connell; J R Morphy; J J Reynolds; M C Meikle
Journal:  Biochem J       Date:  1995-05-15       Impact factor: 3.857

6.  H-31 human breast cancer cells stimulate type I collagenase production in osteoblast-like cells and induce bone resorption.

Authors:  K Ohishi; N Fujita; Y Morinaga; T Tsuruo
Journal:  Clin Exp Metastasis       Date:  1995-07       Impact factor: 5.150

7.  Soluble factors produced by PC-3 prostate cells decrease collagen content and mineralisation rate in fetal rat osteoblasts in culture.

Authors:  J F Santibáñez; S Silva; J Martínez
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

8.  Excessive dietary intake of vitamin A reduces skull bone thickness in mice.

Authors:  Thomas Lind; Caroline Öhman; Gabriela Calounova; Annica Rasmusson; Göran Andersson; Gunnar Pejler; Håkan Melhus
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.